HC Wainwright Issues Negative Outlook for MLTX Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Stock analysts at HC Wainwright cut their Q1 2026 earnings estimates for shares of MoonLake Immunotherapeutics in a report released on Monday, March 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.86) per share for the quarter, down from their previous forecast of ($0.68). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.75) EPS, Q4 2026 earnings at ($0.72) EPS and FY2026 earnings at ($3.10) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, hitting analysts’ consensus estimates of ($0.92). During the same period in the prior year, the firm posted ($0.72) EPS.

Several other brokerages also recently issued reports on MLTX. The Goldman Sachs Group downgraded MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and raised their price target for the company from $8.00 to $10.00 in a report on Wednesday, January 14th. Royal Bank Of Canada upped their price objective on shares of MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the company a “sector perform” rating in a report on Monday. BTIG Research raised their target price on shares of MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Oppenheimer lifted their target price on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Tuesday, February 24th. Finally, Zacks Research upgraded shares of MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $27.85.

MoonLake Immunotherapeutics Stock Performance

MLTX opened at $18.14 on Thursday. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The business has a 50 day moving average of $15.88 and a 200-day moving average of $22.28. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -5.15 and a beta of 1.20.

Insider Activity

In related news, CEO Da Silva Jorge Santos sold 130,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the transaction, the chief executive officer directly owned 2,948,577 shares of the company’s stock, valued at approximately $44,464,541.16. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kristian Reich sold 130,000 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the completion of the sale, the insider directly owned 72,908 shares of the company’s stock, valued at $1,099,452.64. This represents a 64.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 402,908 shares of company stock worth $5,987,162 over the last 90 days. 12.02% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of large investors have recently added to or reduced their stakes in MLTX. Millennium Management LLC raised its holdings in MoonLake Immunotherapeutics by 3,343.2% in the 1st quarter. Millennium Management LLC now owns 344,320 shares of the company’s stock valued at $13,453,000 after acquiring an additional 334,320 shares in the last quarter. Geode Capital Management LLC increased its position in shares of MoonLake Immunotherapeutics by 0.9% in the second quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock worth $2,809,000 after purchasing an additional 559 shares during the period. JPMorgan Chase & Co. raised its stake in MoonLake Immunotherapeutics by 4,584.5% in the second quarter. JPMorgan Chase & Co. now owns 39,397 shares of the company’s stock valued at $1,860,000 after purchasing an additional 38,556 shares in the last quarter. Legal & General Group Plc lifted its position in MoonLake Immunotherapeutics by 7.3% during the second quarter. Legal & General Group Plc now owns 20,905 shares of the company’s stock worth $987,000 after purchasing an additional 1,425 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new stake in MoonLake Immunotherapeutics during the second quarter worth about $74,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.